Since the introduction of transjugular intrahepatic portosystemic shunt (TIPS) 10 years ago, it has been used increasingly in the management of portal hypertension and its complications. TIPS is now considered the procedure of choice for management of refractory variceal bleeding. Its role in the management of refractory ascites, hepatic hydrothorax, hepatorenal syndrome, and hepatopulmonary syndrome still awaits further prospective studies. The two main complications of TIPS are hepatic encephalopathy and shunt malfunction. Generally, TIPS stenosis or occlusion is a major drawback requiring routine surveillance of TIPS with doppler ultrasound. Venography with balloon dilation of the stent or placement of serial or parallel stents may be required in some cases. Promising modalities of preventing TIPS malfunction (e.g., brachytherapy, covered stents, or anti-platelet derived growth factor) are currently being investigated.
Portal hypertension is defined as a portal vein pressure that is greater than 10 mmHg (normal 5-10 mmHg)6 or a hepatic venous pressure gradient (HVPG) of >5 mmHg.7 Portal hypertension occurs because there is increased resistance to portal blood flow. Increased blood flow from splanchnic circulation also contributes to this increase in portal vein pressures. 6 Complications of portal hypertension include variceal bleeding, ascites, hepatic hydrothorax, hepatopulmonary syndrome, hepatorenal syndrome, and hepatic encephalopathy. Except for hepatic encephalopathy, management for most of these complications has been focused on lowering portal vein pressures (or HVPG) that can be achieved by use of medications or by creation of surgical shunts. The advent of TIPS has offered an alternative to these traditional strategies. Optimal treatment of patients with portal hypertension will ultimately depend on the severity of liver disease and the transplant potential of the patient.
HISTORY
In 1969, Rosch et al. introduced a new method of percutaneously creating a shunt between the hepatic and portal veins to decompress the portal venous system (Fig. 2 ).8 They later reported the use of this technique in a larger group of animals using different types of stents to keep the tract open. Silastic or teflon tubing or silicone-coated coil springs were used to bridge the shunt through the liver parenchyma. The procedure was also performed on human cadavers.9 Migration of stents and shunt occlusion were problems encountered during the early phase of TIPS development.9 Balloon angioplasty used to create larger tract diameters was introduced in the 1970s. 10 The first clinical application of TIPS was in a patient with variceal bleeding reported by Colapinto et al. in 1982.11 Balloon expandable stents came into use for the first time in 1985 in dogs with experimentally induced portal hypertension.12
They were able to achieve longer primary and primary-assisted patencies of up to 9 months. Self-expanding metallic stents were first reported in 1987 13 and the first clinical use of metallic stents was reported by Rossle et al. in 1989 using the Palmaz stent.14
FIG. 2. TIPS timeline.

TECHNIQUE
Pre-TIPS Placement Preparation
A doppler ultrasound is performed to assess the size and patency of portal and hepatic venous systems. [15] [16] [17] Intravenous antibiotics are given on call during the procedure. First generation cephalosporins are generally used although some radiologists prefer broad-spectrum antibiotics. 18, 19 Coagulopathy is very common in these patients and some authors recommend correction if platelets are <60,000 and international normalized ratio (INR) is >1. 8.16 Paracentesis is performed in patients with tense ascites. 17 Procedure Ovid: Transjugular Intrahepatic Portosystemic Shunts (TIPS): A Decade L... http://0-ovidsp.tx.ovid.com.impulse.ucdenver.edu/sp-3.4.1b/ovidweb.cgi 2 of 26 6/10/2011 9:49 AM
The procedure is usually performed with conscious sedation. 16 Patients who have massive bleeding and are hemodynamically unstable with a Blakemore tube in place require intubation and mechanical ventilation for better airway management. 20 The right internal jugular vein approach is preferred because it provides a straight path into the infrahepatic inferior vena cava (IVC). 16 
CONTRAINDICATIONS AND INDICATIONS
Careful preprocedural evaluation must be performed in every patient referred for TIPS placement. In certain groups of patients, TIPS placement should not be attempted. The absolute and relative contraindications are listed in Table 1 .17,26 Currently, there is agreement among experts on the accepted indications for TIPS placement. 17, 26 These are presented in Table 2 . There are other instances where TIPS seems to be a promising modality, but data to support the use of TIPS in these instances is still lacking.17,26 Clinicians who are making decisions regarding TIPS placement should take into consideration the expertise and facilities available locally. TIPS placement generally requires a multidisciplinary team consisting of hepatologists, hepatobiliary surgeons, and interventional radiologists.
This review will discuss the evidence supporting the accepted and promising indications for TIPS at the present time. 
VARICEAL BLEEDING AND TIPS
One of the complications of portal hypertension is variceal bleeding. A hepatic venous pressure gradient or portosystemic gradient of >12 mmHg is generally regarded as the cut-off point for an increased likelihood for variceal bleeding 27; therefore, therapy is instituted with the goal of reducing this gradient to <12 mmHg 28 or to at least 20% from the baseline HVPG.29 Management of variceal bleeding consists of three different phases: Prevention of the first variceal bleed (primary prophylaxis), management of active variceal bleed, and prevention of recurrent variceal bleed (secondary prophylaxis). TIPS, because of its favorable effects on portosytemic gradient, is used increasingly in variceal bleeding, specifically in the management of active variceal bleeding and in the secondary prophylaxis of variceal bleed.
Uncontrolled Acute Variceal Bleed
Currently, first line of management for acute variceal bleeding is endoscopic variceal band ligation or endoscopic sclerotherapy.30 Adjunctive management include vasopressin plus nitroglycerin, somatostatin, octreotide, or terlipressin. However, endoscopic therapy in combination with pharmacologic therapy fails to achieve hemostasis in 10%-20% of all cases.31,32 Standard therapy for medically and endoscopically uncontrolled acute variceal bleeding is balloon tamponade followed by either devascularization 33,34 or surgical portosystemic shunting.34-37 However, both of these surgical interventions are associated with high mortality rates in the emergency setting.32,34-36 In addition, most of these patients are often considered unfit to undergo surgery. TIPS, because it is less invasive and non-operative, is used increasingly in these patients.
Six uncontrolled studies have been published that evaluated the efficacy of TIPS for acute variceal bleeding refractory to endoscopic management.2,32,35,38-40 One study compared TIPS to esophageal transection in a nonrandomized fashion (Table 3) .31 Fig. 3) . One year survival rates in all studies except two are similar between patients treated with TIPS and those treated with endoscopy (Fig. 4) . This is probably due to both the small sample sizes of the studies and the fact that these studies were designed with rebleeding and not mortality as an endpoint. In addition, a proportion of patients randomized to endoscopic treatment were crossed over to TIPS after endoscopic treatment failure. These patients probably survived because their death from variceal rebleeding was prevented by salvage TIPS; however, they are analyzed in an intention to treat fashion under the endoscopy treatment group. 61 In the only study that showed a survival advantage for TIPS, patients who underwent EST and had variceal rebleeding died before undergoing salvage The only study that did not show a difference in rebleeding in favor of TIPS had a very low variceal rebleeding rate in the patients treated with EST (25% vs. 50% in other studies). The time to randomization in this study was longer than that of the other ten trials. An important factor in determining rebleeding and survival outcomes in clinical trials on variceal bleeding is the time from the last variceal bleed to randomization. 62 The longer time to randomization in this study may have influenced its outcomes as patients who were at higher risk of rebleeding may have already been New or worsening hepatic encephalopathy was seen in significantly more patients treated with TIPS than with EST or EVBL (Fig. 5) .50,52-55 The incidence of new or worsened hepatic encephalopathy ranged from 16%-55% (Table 4) .
Most of these episodes were easily controlled by dietary protein restriction and lactulose. A few cases of medically refractory cases of hepatic encephalopathy required revision of the stent and placement of a smaller stent.55,56 TIPS malfunction was fairly common but was associated with the clinical consequence of variceal rebleeding in only a few cases. Variceal rebleeding, however, in the TIPS group was almost always related to either TIPS occlusion or stenosis.50,54,56
Rates of encephalopathy in patients undergoing TIPS or endoscopic therapy from the randomized controlled trials on the prevention of variceal rebleeding. * p < 0.05
These studies show that TIPS is more effective than conventional treatment for the prevention of variceal rebleeding. However, because (1) EST or EVBL is more widely available than TIPS, (2) hepatic encephalopathy is more common with TIPS, and (3) survival is not improved by TIPS, TIPS cannot be recommended over EST or EVBL as the first line of treatment in the prevention of variceal rebleeding. It is, however, a very attractive option in medically refractory recurrent variceal bleeding.
Prevention of Recurrent Variceal Bleeding Despite Adequate Pharmacologic and Endoscopic Treatment
Recurrent bleeding despite adequate pharmacologic and endoscopic treatment generally requires variceal decompression.6 TIPS has provided an alternative to surgical shunts in the treatment of these patients. Surgical shunts have been the preferred treatment in patients with relatively preserved liver function (Child-Pugh class A or B), mainly because they are less prone to occlusion or stenosis and are highly effective in the prevention of rebleeding.
TIPS has largely supplanted surgical shunts in the more critically ill patients who are poor surgical risks.29
There is only one randomized controlled trial that compares TIPS with surgical shunts in the management of recurrent variceal bleeding after failing nonoperative treatment.63,64 Forty patients underwent TIPS and forty underwent 8 mm H-graft portocaval shunt (HGPCS) placement. Results show that, with at least one year of follow-up, patients undergoing TIPS had more episodes of variceal rebleeding than those who receive HGPCS placement. The incidence of hepatic encephalopathy (HE) was similar in both groups. Mortality rate was not significantly different between treatment groups. There are, however, several issues with this study. (1) Randomization was done by pairs;
therefore it is unclear if true randomization occurred. This may account for the significant difference in the number of patients undergoing "urgent" shunting (28% TIPS vs. 8% HGPCS, p < 0.05).65 (2) Follow-up was short, with a mean of one year. (3) The use of general anesthesia in all patients undergoing TIPS is unusual and raises the issue of the technical expertise of the interventional radiologists. (4) It is unclear from the study how long it took to randomize the patients from the last episode of variceal bleeding and how many previous variceal bleeding episodes the patients in each group had. This study has not settled the issue of how variceal decompression should be achieved in medically refractory variceal bleeding, but it emphasizes the need for further studies in this area.66
Currently, surgical decompression is recommended for medically refractory variceal bleeding in good surgical risk patients and in patients with preserved liver function (Child's class A or B).1,26,29 TIPS is the accepted treatment for those who are not surgical candidates and who have severe liver dysfunction (Child's class C).29 A multicenter study comparing distal splenorenal shunt with TIPS for medically refractory variceal bleeding in patients with well-preserved liver function is currently underway.
TIPS AND REFRACTORY ASCITES, HEPATIC HYDROTHORAX, AND HEPATORENAL SYNDROME
Refractory Ascites
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In the large series of patients in whom TIPS was performed for variceal bleeding, a substantial number of patients had either a concomitant resolution of their ascites or had improved ascites control.42,44,48 This is likely due to the fact that TIPS acts as a side-to-side portacaval shunt and, by reducing sinusoidal hypertension, has a positive impact on ascites. The use of TIPS in all patient with ascites, however, is not warranted because of the morbidity associated with TIPS, e.g., encephalopathy, shunt malfunction, or potential worsening of liver function. Its use in refractory ascites (defined as ascites that cannot be mobilized or the recurrence of which cannot be satisfactorily prevented by medical therapy 67) deserves consideration.
The improvement in ascites after TIPS placement is paralleled by an increased natriuresis.68-70 Natriuresis occurs because TIPS placement decreases plasma levels of renin and aldosterone and increases creatinine clearance.68-70
These humoral and renal hemodynamic changes are thought to occur in association with the reduction in sinusoidal pressure after TIPS placement.71 In fact, the serum ascites-albumin gradient narrows shortly after TIPS placement.72
TIPS has been evaluated in refractory ascites in several uncontrolled series of patients.68,70,73-80 These studies, summarized in Table 5 , illustrate three important points regarding the role of TIPS in refractory ascites.
TABLE 5. TIPS in refractory ascites
(1) TIPS can be effective in refractory ascites, eliminating the need for paracentesis in 50%-92%81 of patients or decreasing the required doses of diuretics.
(2) TIPS is associated with significant rate of hepatic encephalopathy (12%-50%).
(3) TIPS for refractory ascites does not improve survival. Survival rates at one year (33%-76%) remain essentially similar to the rates reported for repeated paracentesis and peritoneousvenous shunts for refractory ascites.82
There were no consistent clinical or biochemical predictors of response of refractory ascites to TIPS prior to TIPS; however, nonresponders were generally older,71 had more severe liver disease,73,77,83 or had organic renal disease.68,77,83,84 It has been suggested that a low pre-TIPS shunt fraction that increases after TIPS placement may predict good response of refractory ascites to TIPS.85
To date, there are only two small randomized controlled trials comparing TIPS and repeated paracentesis for refractory ascites-one published 86 and another in abstract form. 87 Lebrec et al. found that TIPS was more effective than paracentesis in managing refractory ascites in a group consisting of patients with Child's class B and C cirrhosis. 86 This result was duplicated by Ochs et al. 87 Survival rates were similar in Child's class B patients who underwent either TIPS or paracentesis.86,87 Child's class C patients who received TIPS, however, had a significantly lower survival rate than their counterparts who had repeated paracentesis.86 Child's C patients also had a poorer survival rate in one other series that used TIPS to treat refractory ascites.80
Based on the available data, TIPS is a reasonable alternative to conventional treatment in patients with refractory ascites but requires critical deliberation in patients with Child's C cirrhosis, advanced age, or renal failure. Larger randomized, controlled trials are needed to identify subgroups of patients with refractory ascites that respond best to TIPS.88 A multicenter trial comparing TIPS and large volume paracentesis is currently underway.
Refractory Hepatic Hydrothorax
Hepatic hydrothorax is considered refractory when thoracentesis needs to be performed at least weekly in spite of adequate medical therapy (e.g., sodium restriction and diuretics).89 There are few safe and effective therapeutic options for patients with refractory hepatic hydrothorax. The only definitive treatment is liver transplantation.90
Although combined chemical pleurodesis and peritoneovenous shunts can control hydrothorax, their associated problem with dye toxicity. There is a need to undertake studies that will evaluate the use of TIPS in a randomized and controlled fashion in the treatment of hepatorenal syndrome. The lack of effective alternative treatment modalities and the almost universally fatal outcome of HRS without intervention make TIPS an attractive option in the treatment of HRS in nontransplant candidates and as a bridge to liver transplantation in those who are.
TIPS AND BUDD-CHIARI SYNDROME AND VENO-OCCLUSIVE DISEASE
The TIPS has also been used to treat complications of portal hypertension in patients with veno-occlusive disease, either as a complication of chemotherapy 110 or bone marrow transplantation.111-113 TIPS was successfully placed in a series of six patients with veno-occlusive disease after bone marrow transplantation.111 There was no benefit seen in three patients as they died immediately after TIPS placement. Two patients had improvement but subsequently succumbed to multiorgan failure and recurrent lymphoma. Only one patient had sustained clinical improvement with a follow-up of 36 weeks.111
OTHER USES FOR TIPS
TIPS has been used in a number of other conditions including hepatopulmonary syndrome,114-116 gastric varices,117 ectopic intestinal varices,118-121 stomal varices,122-124 and variceal bleeding in the setting of hepatocellular carcinoma.125 Due to the lack of extensive data, these are not discussed further.
COMPLICATIONS OF TIPS
TIPS placement has a reported procedure-related morbidity rate of 10% and a procedure-related mortality rate of 2%.126 There are many reported complications of TIPS. 
TIPS AND HEPATIC ENCEPHALOPATHY
Hepatic encephalopathy is one of the long-term complications of TIPS placement.127,128 It is difficult to determine the true incidence of post-TIPS hepatic encephalopathy from the literature.127 This can be explained by a number of reasons. The definition of hepatic encephalopathy and the method of making the diagnosis of hepatic encephalopathy varies from study to study. Some authors report only new or worsened hepatic encephalopathy whereas others report all cases of hepatic encephalopathy after TIPS placement. Moreover, most patients are prophylactically placed on lactulose, a fact that can lead to underestimation of the true incidence of hepatic encephalopathy. The trials that compared TIPS with endoscopic treatment for the prevention of variceal bleeding showed an incidence of post-TIPS encephalopathy of 23%-55%, which was significantly higher than the incidence of HE after endoscopic treatment.50-58 Larger prospective series report an incidence of new or worsened hepatic encephalopathy of 13%-44%.44,127,129-132
The pathogenesis of post-TIPS hepatic encephalopathy is multifactorial, mainly related to either decreased portal flow due to the diversion of portal flow through the TIPS and away from the liver or increased bioavailability of gut-derived toxins. Shunt malfunction is defined as symptomatic or asymptomatic occlusion or stenosis (>50% diameter narrowing) that should be associated with a portosystemic gradient greater than 12 mmHg. Some authors consider stenosis to be hemodynamically significant if the portosystemic gradient is greater than 15 mmHg or greater than a 20% increase from the immediate post-TIPS gradient if the portosystemic gradient is <15 mmHg. 139, 140 There is a wide range of shunt malfunction rates reported in the literature from 17%-50% within six months to 23%-87% within the first year.
Differences in the definition of shunt malfunction, the manner in which surveillance is conducted, and the length and frequency of follow-up account for this wide variation in the reported rates of shunt malfunction.139,140 Saxon et al.
have suggested that the guidelines for stent patency established for endovascular procedures be used in the studies that evaluate TIPS patency.140 Primary patency includes only TIPS that are patent without intervention. Primary assisted patency includes TIPS that are primarily patent and those that are patent after a stenosis has been revised.
Patency does not include stents that have occluded. Secondary patency includes all patent stents even those that have occluded and been re-opened.140,141 Primary patency, primary assisted patency, and secondary patency rates from several large series on TIPS are presented in Table 7 .43,142-145 
TIPS Surveillance
Ultrasound has been the screening procedure of choice for TIPS patency.156 A baseline ultrasound is performed 24 hours after TIPS placement to assess patency, to establish baseline flow measurements, and to evaluate for possible procedural complications such as hematomas, hepatic infarction, or hemoperitoneum.156 Subsequent sonographic screening is suggested at six weeks, three months, six months, and every six months thereafter.
The absence of flow in the TIPS stent on ultrasound is very useful in detecting shunt thrombosis. The most important sonographic criteria for TIPS stenosis has been peak midshunt or intrastent velocity. A value of <50-60 cm/s has been quoted to predict hemodynamically significant stenosis with a sensitivity of 86%-100% and a specificity of 54-98%.143,158,159 Two studies however showed that a peak midshunt velocity of <50-60 cm/s had a low sensitivity of 25%-35% indicating that it is a poor screening parameter for stenosis.148,149 A combination of two or several sonographic criteria may be the optimal method of screening for shunt stenosis. Casado et al.135 found a low sensitivity for single sonographic criteria with 42% for peak flow velocity <50 cm/s, 65% for reversal of intrahepatic blood flow, and 70% for mean portal flow velocity < 19 cm/s. A combination of at least two of these criteria results in a higher sensitivity of 91%.
Venography is the gold standard for the diagnosis of shunt occlusion or stenosis. This should be performed whenever a screening sonography suggests stenosis or whenever the patient has documented recurrence of variceal bleeding even in the face of a normal ultrasound study. Because we still do not have the optimal screening method and variceal rebleeding carries a significant mortality rate, venography is suggested by some authorities to be performed at six month intervals for at least three years.161
The role of endoscopy in TIPS surveillance is not known. Sanyal et al. 161 found that recurrence of varices on endoscopy after initial disappearance after TIPS is associated with recurrent portal hypertension in all cases and therefore needs venography. They also found that endoscopy was more sensitive in the detection of recurrent portal hypertension than ultrasound in the group of patients with documented initial disappearance of varices.161 Endoscopy should be the first test to determine the etiology of the gastrointestinal bleed and to institute endoscopic treatment if appropriate in a patient who presents with upper gastrointestinal bleeding and who has a TIPS in place.
Treatment of TIPS Malfunction
Once TIPS malfunction is detected, therapeutic interventional procedures can be performed at the time of the venogram. Recanalization may be attempted percutaneously in shunt thrombosis or a parallel stent may be placed if recanalization is not possible. For TIPS stenosis, either angioplasty or further stent placement may be performed.162
Surgical shunt is an option in those patients who cannot be corrected percutaneously. There is a need to study the application of brachytherapy in the prevention of TIPS malfunction from pseudointimal hyperplasia.
Prevention of TIPS Malfunction
SUMMARY
Since its introduction ten years ago, TIPS has gone from being a novelty to being an important therapeutic modality of portal hypertension. It is the procedure of choice in refractory active variceal bleeding and refractory recurrent variceal bleeding in poor surgical risk patients. Its role in good surgical risk patients with refractory recurrent variceal bleeding still needs to be defined. The use of TIPS in the other complications of portal hypertension (e.g., prevention of recurrent variceal bleed after the index bleed, refractory ascites, hepatic hydrothorax, hepatorenal syndrome) remains to be determined and awaits further study. Hepatic encephalopathy is increased after TIPS placement but is easily controlled with medical therapy in most patients. Shunt malfunction is the main limitation Table 1   Table 2   Table 3   Table 4 Fig. 3 Table 5   Table 6   Table 7 Ovid: Transjugular Intrahepatic Portosystemic Shunts (TIPS): A Decade L... http://0-ovidsp.tx.ovid.com.impulse.ucdenver.edu/sp-3.4.1b/ovidweb.cgi 25 of 26 6/10/2011 9:49 AM
